Telomir Pharmaceuticals announced fresh preclinical results demonstrating that its lead candidate Telomir-1 significantly lowers prostate-specific antigen (PSA) levels in androgen-responsive human prostate cancer cells. The company claims that when LNCaP cells were stimulated with dihydrotestosterone (DHT), Telomir-1 dose-dependently reduced PSA secretion—a widely accepted biomarker for tumor activity in prostate cancer.
In addition to the PSA reduction, the report references prior data showing that Telomir-1 can modulate intracellular iron levels, reverse abnormal DNA methylation of key tumour-suppressor genes, and impair viability in various aggressive cancer models including leukemia, triple-negative breast cancer, pancreatic cancer, and androgen-independent prostate cancer.
Telomir describes this latest finding as supporting its broader therapeutic strategy: by targeting core metabolic and epigenetic vulnerabilities (iron homeostasis, redox balance, histone/DNA methylation), Telomir-1 may act across a range of cancer types—potentially offering alternative treatment paths beyond hormone-targeted or cytotoxic therapies.
That said, the data remain strictly preclinical and derived from cell-line experiments. Telomir has not yet reported animal-model or human clinical data for prostate cancer, and thus the compound’s safety, efficacy, therapeutic window, and real-world treatment potential remain untested.
